Alnylam Pharmaceuticals CMO sells shares worth $14.99 million

Pushkal Garg, Chief Medical (TASE:PMCN) Officer and Executive Vice President of Development & Medical Affairs at Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), recently sold a significant portion of his holdings in the company. On January 27, Garg sold 52,592 shares of common stock at a price of $285.00 per share, amounting to a total transaction value of approximately $14.99 million.

The sale was part of a pre-arranged trading plan under Rule 10b5-1, which Garg adopted on September 11, 2024. Prior to the sale, Garg exercised options to acquire 48,876 shares at $88.95 per share, totaling $4.35 million, which were set to expire on December 18, 2025. The company maintains strong financial health with a current ratio of 2.75 and impressive revenue growth of 21.54%. For deeper insights into Alnylam’s financial metrics and more exclusive ProTips, visit InvestingPro.

After these transactions, Garg’s direct ownership of Alnylam Pharmaceuticals’ common stock stands at 11,989 shares. Additionally, he holds 431 shares indirectly through a managed account and 250 shares through a trust co-managed by his spouse. With an overall financial health score rated as "GOOD" by InvestingPro, the company continues to maintain a solid market position.

In other recent news, Alnylam Pharmaceuticals has reported significant developments in its financial performance and product pipeline. The company announced its fourth quarter and full-year 2024 financial results, revealing expected net product revenues of $452 million for the fourth quarter and $1.65 billion for the full year, surpassing estimates. For 2025, Alnylam has set a net product revenue guidance range between $2.05 billion and $2.25 billion, with the TTR and Ultra Rare franchises expected to contribute significantly.

H.C. Wainwright maintained a Buy rating on Alnylam, emphasizing the company’s promising financial trajectory. Stifel analysts also maintained a positive outlook on Alnylam shares, reiterating their Buy rating. They highlighted Alnylam’s leadership in the field of RNAi therapeutics, which represents a novel approach in gene silencing and regulation.

Alnylam also anticipates FDA approval of AMVUTTRA for patients with ATTR cardiomyopathy by March 23, 2025. This is a key component of the company’s strategy, and achieving the projected revenue guidance would set Alnylam on a path to non-GAAP profitability in 2025.

Canaccord Genuity maintained a Buy rating on Alnylam, underscoring the company’s strong positioning in the ATTR-CM treatment market. BMO Capital also retained its Outperform rating on Alnylam, bolstered by the recent FDA approval of Alnylam’s drug, Attruby.

These are the recent developments in Alnylam Pharmaceuticals that investors should be aware of.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.